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BACKGROUND: Nitric oxide (NO) production is increased
in inflammatory bowel disease (IBD), and measure-
ment of NO metabolites may be useful for monitoring
disease activity.
Aims  and objectives: To  characterise  urinary  nitrite
levels,  a  stable  metabolite  of  NO,  in  IBD  and  to
evaluate its potential as a marker of disease activity.
Methods: Twelve-hour urinary nitrites were measured
by the microplate  assay method in 46 patients with
IBD (active; n = 32). Urinary samples from 16 healthy
individuals served as controls.
Results: Increased  levels  of  urinary  nitrites  were
found  in  patients  with  active  IBD  compared  with
those  with  inactive  IBD.  Twenty-eight  out  of  32
patients (87.5%) with active IBD had detectable levels
of  nitrite  in  their  urine  as  compared  with  2/14
(14.3%)  patients  with  inactive  IBD.  None  of  the  16
healthy  controls  had  detectable  urinary  nitrite.
Twelve-hour urinary nitrite in active compared with
inactive IBD: 5 ±  0.7 versus 0.1 ±  0.04 m mol (P < 0.05).
There was good correlation between urinary nitrite
and some markers of disease activity in IBD such as
C-reactive  protein  and  microalbuminuria  but  not
with erythrocyte sedimentation rate.
Conclusions: Increased levels of nitrite were detected
in urine of patients with active IBD, consistent with
increased  NO  synthesis.  This  simple  assay  may  be
exploited as a potential marker of disease activity in
IBD.
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Introduction
Nitric oxide (NO) is increasingly recognised to play a
pivotal role in numerous physiological and pathophy-
siological processes since it was initially characterised
as an endothelium-derived relaxing  factor.1–3 NO is
formed from the conversion of L-arginine to citrulline
via  nitric  oxide  synthase  (NOS),4 which  exists  in
several isoforms and can be found in numerous cell
types including endothelial cells, neutrophils, macro-
phages, hepatocytes, enterocytes, neurons, and vas-
cular smooth muscle.5–8 In the gastrointestinal tract,
NO participates in neurotransmission,9 smooth mus-
cle relaxation,10 intestinal secretion, maintenance of
intestinal blood flow and as an inflammatory media-
tor.10,11 Recent studies have demonstrated that NO
production is increased in  inflammatory bowel dis-
ease (IBD).12–17 Factors influencing a physiological or
pathological  outcome  subsequent  to  increased  NO
production include the redox state of the molecule,
its local concentration and its potential to form toxic
intermediary metabolites.2,7
NO is ultimately metabolised to stable end products
that  include  nitrite  and  nitrate.2,18,19 The  relative
amount  of  nitrite  and  nitrate  produced  by  NO
breakdown depends on the pH and redox state of the
environment in which it is produced.18,19 In experi-
mental animals, urinary nitrite reflects systemic rather
than renal production of NO. Nitrite has been used as
a marker of NO production in culture fluids, plasma,
synovial fluid and urine.20,21 It has been found that
plasma nitrite is increased in patients with rheuma-
toid arthritis compared with healthy controls and also
that levels were significantly  higher in  the synovial
fluid than in plasma.21 Interleukin II immunotherapy
causes  a  significant  elevation in  plasma  nitrate lev-
els.22 Plasma nitrite levels have also been detected in
other  conditions  such  as  sepsis,23 cirrhosis24 and
fulminant hepatic failure,25 and in the postoperative
period.26
Estimation  of  nitrite  is  a  useful  marker  of  NO
synthesis and may potentially be used as an indicator
of disease activity in chronic inflammatory conditions
such as IBD.
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Patients
Forty-six patients were enrolled for the study. Thirty-
two (69%) patients had active IBD at the time of study.
Active IBD was defined as a Harvey–Bradshaw index
(HBI)27 > 3. Twenty-five patients had Crohn’s disease
(CD)  and  21  patients  had  ulcerative  colitis  (UC)
(pancolitis; n = 6). Sixteen healthy laboratory person-
nel served as controls. Thirty patients were receiving
oral aminosalicyclates, four  patients  were  receiving
corticosteroids and  15  patients  were  receiving  no
medication at the time of urinary sampling.
Urinary nitrite estimation
Timed 12-h urine collections were performed on all
patients.  A  microplate  assay  method  was  used  to
quantify  urinary  nitrite.  An  equal  volume  of  the
Griess reagent (0.1% sulphonide, 0.1% naphthylethy-
lenediamine dihydrochloride, 2.5% phosphuric acid)
was  added  to  urine  samples  or  to  urine  nitrite
standards  and  incubated  at  room  temperature  for
10min. Absorbance was  performed  by  spectropho-
tometry  at  540nm.27 The  limit  of  detection  of
nitrite was 1 micromole per litre (1 m mol/l). Urinary
nitrite  concentration was  determined and 12-h  uri-
nary nitrite production calculated.
Assessment of disease activity
Disease activity was measured using the HBI, eryth-
rocyte  sedimentation  rate  (ESR)  and  C-reactive
protein  (CRP)  and  microalbuminuria.  CRP  and
microalbuminuria  were  measured  by  the  immuno-
turbometric  method  (Behring,  Germany)  as  pre-
viously described.28
Statistics
The  Wilcoxon  rank  sum  test  was  used  for  non-
parametric data and the non-paired Student t-test for
parametric data. Correlations were determined using
simple regression analysis. Statistics were performed
using Statworks software.
Ethics
The study was approved by the Joint Ethics Commit-
tee  of  St.  James’s  Hospital  and Adelaid  and  Meath
Hospital  incorporating  National  Children’s  hospital
Tallaght. Written informed consent was obtained from
all  study  subjects prior to  phlebotomy and urinary
sampling.
Results
Urinary nitrite in IBD
Twenty of 32 (87.5%)  patients with active IBD had
detectable urinary nitrite. In contrast, only two of 14
(14.2%) patients with inactive IBD had low levels of
urinary nitrite. None of the 16 healthy controls had
any nitrite in their urine. Twelve-hour urinary nitrite
in  active  compared  with  inactive  IBD  was  5  ±
0.7 m mol versus 0.1 ± 0.04 m mol/12h (P < 0.05) (Fig.
1). Urinary nitrite in controls was 0 ± 0 m mol (P <
0.05). There was no difference in urinary nitrite level
between patients with CD and UC: 4.1 ± 0.8 m mol/
12h versus 2.2 ± 0.44 m mol/12h (P = not significant
(NS)).  The  urinary  nitrite  concentration  was  also
significantly higher in patients with active IBD com-
pared  with  inactive  IBD  (25.5  ±  6.8 m mol/l  versus
0.15 ± 0.05 m mol/l, respectively; P < 0.05).
Comparing urinary nitrite in active CD and inactive
CD, urinary nitrite was 10 ± 2.8 m mol/12h versus 0 ±
0 m mol/12h (P < 0.05) (Fig. 2). In patients with active
UC compared with inactive UC, urinary nitrite was 16
± 3.7m mol/12h versus 0 ± 0 m mol/12h (Fig. 2). There
was no difference in  urinary  nitrite levels  between
patients with active disease on treatment compared
with patients on no treatment (9.4 ± 6.8m mol/12h
versus 8.8 ± 1.29m mol/12h; P = NS) (Fig. 3).
Relationship between urinary nitrite and
disease activity markers
Patients with active IBD had significantly higher levels
of microalbuminuria than those with inactive disease.
There  was  a  strong  correlation  between  micro-
albuminuria and urinary nitrite in CD (r = 0.88, P <
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FIG. 1. Timed 12-h urinary nitrite was assayed in patients
with  active  and  inactive  inflammatory  bowel  disease  (as
defined by the Harvey–Bradshaw index (n = 32 and n = 14,
respectively)). * P < 0.05 versus control, ** P < 0.05 versus
active disease.0.01) (Table 1). In contrast, there was no correlation
between microalbuminuria and urinary nitrite in UC
(r <  0.1,  P =  NS)  (Table  1). There  was  a  strong
correlation between urinary nitrite in CD and serum
CRP  level  (r =  0.66,  P <  0.05).  The  correlation
between urinary nitrite and serum CRP in UC did not
reach statistical significance (r = 0.47, P = NS). The
levels of CRP were higher in urinary nitrite-positive
patients  than  in  nitrite-negative  patients  (32.5  ±
4.9 m mol/l versus 5.7 ± 1.9m mol/l; P < 0.05).
There was no significant correlation between levels
of  urinary  nitrite  and  HBI.  ESR  was  higher  in  the
active IBD group compared with the inactive group
(27.6 ± 20 versus 10.7 ± 3; P = 0.05). There was no
difference  in  the  ESR  in  the  urinary  nitrite-positive
patients  compared with the  urinary  nitrite-negative
patients (22.8 ± 15mm versus 23 ± 2.5mm in the first
hour; P = NS).
Discussion
This  study  demonstrates  that  urinary  nitrite  was
detectable in  IBD  and higher  levels  were observed
during  active  disease. These  data  support  previous
findings of increased NO generation in active IBD.18,19
Previous investigations have demonstrated increased
plasma  nitrite/nitrate  levels  and  increased  mucosal
citrulline production in active IBD. Elevated urinary
nitrate and nitrite were not exclusive to IBD but have
been observed in other inflammatory conditions of
the  bowel  including  infectious  and  radiation enter-
ocolitis.18 In our study, urinary nitrite levels appeared
to correlate with laboratory indices of disease activity
in  Crohn’s  disease  but  not  in  ulcerative  colitis.
Evidence for increased NO production has also been
demonstrated in experimental models of IBD. Peroxy-
nitrite-induced colitis in experimental models can be
ameliorated  by  inducible  NOS  (iNOS)  inhibi-
tors.7,13,29,30 It has also been shown that NOS activity
was increased in the colonic mucosa of patients with
IBD,15,17 and that increased nitrite levels were detec-
ted  in  rectal  diasylate  of  patients  with  active  IBD,
especially in active UC.14,31 But, in the case of CD,
there  is  conflicting  evidence:  low  colonic  NOS
activity in one study,17 and higher NOS activity in the
others.13,15,32,33
The origin  of  urinary  nitrite in  IBD is unknown.
Our observation of similar levels of urinary nitrite in
UC and CD patients despite reported differences in
colonic  levels  of  NOS  may  suggest  that  systemic
production of NO may be a major source of urinary
nitrite in IBD. A potential source of NO production is
the  peripheral  blood  macrophages, following  iNOS
induction in response to pro-inflammatory cytokines
and endotoxins. Furthermore, bacterial translocation
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FIG.  2.  Timed  12-h  urinary  nitrite  stratified  according  to
disease  activity  and  inflammatory  bowel  disease  (IBD)
subtype (Crohn’s disease and ulcerative colitis (UC)). * P <
0.05 versus active disease.
FIG. 3. The effect of concurrent anti-inflammatory medication
on 12-h urinary nitrite was assessed  among patients with
active inflammatory bowel disease (n = 32). No  statistical
difference was detected between the groups.
Table 1. Correlation coefficient (r) between urinary nitrite and
markers  of  disease  activity  (microalbuminuria  and  serum
C-reactive protein (CRP))
Crohn’s disease Ulcerative colitis
Microalbuminuria 0.88* < 0.1
Serum CRP 0.66** 0.47
*P < 0.01, ** P < 0.05.may  be another source of urinary  nitrite.  Endotox-
aemia is  a recognised feature of  IBD,  and bacterial
translocation  has  been  associated  with  increased
urinary  nitrate  production  in  animal  studies.34
Another source of NO may be the intestinal epithelial
cells, which have been shown to possess NO activity
in animal studies.35
We have shown that the levels of  urinary  nitrite
correlate with microalbuminuria and CRP in CD. It is
possible that renal production of NO following pro-
inflammatory stimuli  may  contribute to the urinary
nitrite detected in these subjects. A renal source of
urinary  nitrite  has  also  been  recently  suggested  in
patients with urinary tract infection.36 Previous stud-
ies in experimental models have demonstrated that,
although inflamed glomeruli are capable of producing
nitrite, urinary nitrite in experimental glomerulone-
phritis reflects systemic NO formation as a result of
immune activation rather than glomerular production
of NO.37,38This suggests that, although conversion of
nitrite to nitrate is rapid in vivo, at least some of the
nitrite  produced  systemically  as  a  result  of  NO
production  is  cleared  by  the  kidneys  before  it  is
converted  to  nitrate.  NO  may  contribute  to  the
pathogenesis  of  IBD  through  its  pro-inflammatory
effects  (local  cell  injury,  intestinal  hyperaemia),  its
effects on neurotransmission, fluid secretion and its
ability to induce smooth muscle relaxation.
There are limitations to the application of nitrite
measurement  as  a  marker  of  NO  production  and
routine laboratory marker of disease activity in IBD.
The  additional measurement  of  urinary  nitrate,  the
other  stable  end  product  of  NO  metabolism,  may
provide  further  information  regarding  in  vivo NO
status.39 It  is  conceivable  that  dietary  arginine  or
nitrite  intake  could  have  influenced  urinary  nitrite
levels among this cohort. Nevertheless, urinary nitrite
was not present in healthy individuals at levels within
the detection limits of our assay.
In  conclusion,  patients  with  active  IBD  have
elevated levels of urinary nitrite, a stable end product
of NO. Measurement of urinary nitrite may serve as a
useful marker for monitoring disease activity in IBD.
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